Fortress Biotech, Inc.FBIONASDAQ
LOADING
|||
Switch Symbol:
R&D Expense Growth Under Pressure
Trending lower, below historical average.
Left:
||||
Year-over-year research & development expense growth
Latest
-97.44%
↓ 2781% below average
Average (39q)
3.63%
Historical baseline
Range
High:106.35%
Low:-97.44%
CAGR
+2.5%
Modest growth trend
| Period | Value |
|---|---|
| Q3 2025 | -97.44% |
| Q2 2025 | 106.35% |
| Q1 2025 | -60.38% |
| Q4 2024 | 5.23% |
| Q3 2024 | -25.45% |
| Q2 2024 | -48.99% |
| Q1 2024 | 76.46% |
| Q4 2023 | -30.82% |
| Q3 2023 | -36.69% |
| Q2 2023 | -18.64% |
| Q1 2023 | 12.49% |
| Q4 2022 | 17.45% |
| Q3 2022 | -9.75% |
| Q2 2022 | -9.78% |
| Q1 2022 | -14.71% |
| Q4 2021 | 53.33% |
| Q3 2021 | -17.01% |
| Q2 2021 | 67.88% |
| Q1 2021 | 12.20% |
| Q4 2020 | 30.58% |
| Q3 2020 | -20.36% |
| Q2 2020 | 14.26% |
| Q1 2020 | -36.00% |
| Q4 2019 | 54.68% |
| Q3 2019 | -18.38% |
| Q2 2019 | -21.13% |
| Q1 2019 | -5.30% |
| Q4 2018 | 26.60% |
| Q3 2018 | 13.15% |
| Q2 2018 | -30.20% |
| Q1 2018 | 73.88% |
| Q4 2017 | -11.00% |
| Q3 2017 | 20.08% |
| Q2 2017 | 60.44% |
| Q1 2017 | -20.53% |
| Q4 2016 | 27.16% |
| Q3 2016 | -1.08% |
| Q2 2016 | 7.52% |
| Q1 2016 | 35.84% |
| Q4 2015 | -36.56% |